Dementia vs. Alzheimer’s disease?...

What is the difference between dementia and Alzheimer's disease? Dr. Denise Compton, a...

Can Telemedicine Group Visits...

Telemedicine weight management combines remote coaching, lifestyle guidance and peer...

Video 2: Diagnosing Alzheimer’s:...

Explore how clinicians use cognitive tests, imaging, and biomarker tools to diagnose Alzheimer’s...
HomeVIDEOSImproving the health...

Improving the health and well-being of patients affected by Alzheimer’s disease



Source:

    Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical stage pharmaceutical company focused on improving the health and well-being of patients affected by Alzheimer’s disease and bringing these therapies to market joins eHealth Radio and the and Channels. Listen to interview with host and guests Ram Mukunda and Claudia Grimaldi discuss the following:

– Many people are aware of the symptoms of Alzheimer’s including dementia, but many are unaware of that agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease. Can you explain why?
– How does this condition affect those caring for a patient affected by Alzheimer’s?
– How does your investigational drug IGC-AD1 work to help these patients?
– What are the next steps in bringing this drug to market?
– What other therapies is IGC Pharma working on in Alzheimer’s?
Ram Mukunda is both the founder and Chief Executive Officer of IGC Pharma. Prior to forming IGC Pharma, he was the President, Chief Executive Officer & Director at India Globalization Capital, Inc., Chairman, President & Chief Executive Officer for Techni Bharathi Pvt Ltd. (a subsidiary of India Globalization Capital, Inc.). Ram Mukunda previously occupied the position of Council Member at Jamaica Dairy Development Board, Chairman & Chief Executive Officer of Startec Global Communications Corp., Council Member at Harvard Kennedy School of Government and Council Member at Belfer Center for Science & International Affairs. Ram Mukunda received an undergraduate degree and a graduate degree from the University of Maryland. Claudia Grimaldi has been with IGC for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance, and disclosures. She is currently Vice President, Principal Finance Officer, and Chief Compliance Officer. She is also the Managing Director of Hamsa Biochem SAS, our subsidiary in Colombia, as well as a director of our subsidiary in India. Ms. Grimaldi graduated with a BA in Psychology with high honors from Javeriana University, a top three university in Colombia, and an MBA with high honors from Meredith College in North Carolina. She has completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. Website: People also listened to this:

source

Continue reading

Dementia vs. Alzheimer’s disease? What’s the difference?

What is the difference between dementia and Alzheimer's disease? Dr. Denise Compton, a licensed clinical psychologist who specializes in working with seniors at the Thomas and Lyon Longevity Clinic at the UAMS Institute on Aging, answers the question. To learn...

Can Telemedicine Group Visits Help Maintain Weight Loss?

Telemedicine weight management combines remote coaching, lifestyle guidance and peer support to help people work toward lasting weight loss.

Video 2: Diagnosing Alzheimer’s: Clinical Criteria and Diagnostic Tools

Explore how clinicians use cognitive tests, imaging, and biomarker tools to diagnose Alzheimer’s accurately and efficiently. Series sponsored by Eisai. To watch the full series, visit aapa.org/VitalRounds References and Additional Resources: Alzheimer’s association statement on first blood test used in diagnosing...